Customers for Life?
Motley Fool Money
Intro
This chapter examines the effects of the weight loss drugs ZepBound and Munjaro on various industries, with a particular focus on the medtech sector. It highlights ResMed's stock decline related to sleep apnea treatment and discusses the broader implications for markets and investors.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
